On Tuesday, Tourmaline Bio Inc (NASDAQ: TRML) opened higher 6.37% from the last session, before settling in for the closing price of $15.54. Price fluctuations for TRML have ranged from $12.12 to $48.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 67.11% at the time writing. With a float of $15.60 million, this company’s outstanding shares have now reached $25.64 million.
Let’s determine the extent of company efficiency that accounts for 52 employees. In terms of profitability, gross margin is 49.12%, operating margin of -2628.43%, and the pretax margin is -2146.27%.
Tourmaline Bio Inc (TRML) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tourmaline Bio Inc is 39.16%, while institutional ownership is 63.58%. The most recent insider transaction that took place on Aug 21 ’24, was worth 26,418. In this transaction CEO of this company bought 1,779 shares at a rate of $14.85, taking the stock ownership to the 7,000 shares. Before that another transaction happened on Aug 16 ’24, when Company’s CEO bought 5,221 for $13.79, making the entire transaction worth $71,998. This insider now owns 5,221 shares in total.
Tourmaline Bio Inc (TRML) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 67.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.28% during the next five years compared to -19.23% drop over the previous five years of trading.
Tourmaline Bio Inc (NASDAQ: TRML) Trading Performance Indicators
Check out the current performance indicators for Tourmaline Bio Inc (TRML). In the past quarter, the stock posted a quick ratio of 40.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -3.52 in one year’s time.
Technical Analysis of Tourmaline Bio Inc (TRML)
Looking closely at Tourmaline Bio Inc (NASDAQ: TRML), its last 5-days average volume was 0.33 million, which is a jump from its year-to-date volume of 0.25 million. As of the previous 9 days, the stock’s Stochastic %D was 16.70%. Additionally, its Average True Range was 1.09.
During the past 100 days, Tourmaline Bio Inc’s (TRML) raw stochastic average was set at 8.99%, which indicates a significant decrease from 33.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.30% in the past 14 days, which was lower than the 60.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.89, while its 200-day Moving Average is $19.11. However, in the short run, Tourmaline Bio Inc’s stock first resistance to watch stands at $16.99. Second resistance stands at $17.46. The third major resistance level sits at $18.34. If the price goes on to break the first support level at $15.64, it is likely to go to the next support level at $14.76. Should the price break the second support level, the third support level stands at $14.29.
Tourmaline Bio Inc (NASDAQ: TRML) Key Stats
There are currently 25,643K shares outstanding in the company with a market cap of 423.87 million. Presently, the company’s annual sales total 0 K according to its annual income of -42,120 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -20,180 K.
